Despite limited randomized controlled trial data, routine functional testing after percutaneous coronary intervention (PCI) remains a common practice in clinical settings. However, European and United States guidelines differ in their recommendations regarding this practice, leading to ongoing debates among healthcare professionals.
The POST-PCI trial, conducted in 2022, aimed to provide clarity on the efficacy of routine functional testing after PCI. The study involved 1,706 patients with high-risk anatomical or clinical characteristics and randomized them to undergo either routine functional testing or receive standard care. The primary composite outcome of all-cause death, myocardial infarction (MI), or hospitalization for unstable angina did not differ significantly between the two groups.
Findings and Implications
The results of the POST-PCI trial revealed that routine functional testing after PCI, in the absence of clinical signs or symptoms of recurrent ischemia, did not prevent adverse cardiovascular events. Furthermore, there was no additional benefit of routine functional testing compared to standard care in high-risk patients. The trial findings suggest that post-PCI follow-up should prioritize lifestyle modifications, guideline-based medical therapy, regular exercise, and symptom assessment.
In light of the POST-PCI trial, healthcare professionals need to reassess their approach to post-PCI care. Rather than routinely subjecting patients to functional testing, focusing on optimizing heart-healthy lifestyle habits, adhering to guideline-based medical therapy, and evaluating the presence or absence of symptoms becomes paramount. The trial did not delve into cost-effectiveness or quality-of-life assessment, leaving room for further research in these areas.
By critically analyzing the POST-PCI trial and its implications, healthcare providers can make more informed decisions when it comes to post-PCI care, ultimately improving patient outcomes and optimizing resource utilization.
